While the NCT02221739 (phase 2, n=39) trial (92) didn’t yield strong results (ARR 17.9%, median OS 7.4 months, median PFS 3.8 months), it did provide insight into the abscopal effect, as a responding patient demonstrated CD8 T cell expansion targeting radiation-induced mutations and increased serum interferon-β, which are both indicators of an enhanced anti-tumor immune response. Here, CD8A is linked to neoplasm.